Compound Comparison

Semaglutide vs Retatrutide: One Receptor Against Three

The most established incretin compound set beside the most watched investigational one, and why the comparison is asymmetric in a way that is itself the answer

September 4, 2026·By Adam Reeves · Research Editor, Eppix Labs

Semaglutide and retatrutide get cross-shopped constantly, and the comparison is usually framed as a contest. It is not one. Semaglutide has completed phase 3 programmes, regulatory approvals and cardiovascular outcome data behind it. Retatrutide has a phase 2 dataset and no approval anywhere. The gap in evidence stage is the single most important fact in the comparison, and any read that skips past it is selling something.

This page sets both out on mechanism, evidence, and what a researcher has to verify before working with either. Research-grade material of both compounds is supplied for laboratory use only. Nothing here concerns approved medicines or their use, and nothing here is dosing or medical guidance. The neighbouring comparison is retatrutide vs tirzepatide.

Mechanism: one receptor against three

Semaglutide is a GLP-1 receptor agonist. It is an acylated analogue of human GLP-1 engineered for a long circulating half-life, with substitutions that resist DPP-4 cleavage and a fatty-acid chain that binds albumin.[4] One receptor, heavily optimised.

Retatrutide is a triple agonist at the GIP, GLP-1 and glucagon receptors.[3] The GLP-1 and GIP arms are the incretin mechanisms that tirzepatide already combines. The glucagon arm is what makes retatrutide structurally different from everything approved: in the published literature glucagon-receptor agonism is associated with increased energy expenditure, which is a different lever from the appetite and gastric-emptying effects that carry the GLP-1 class.

That is the whole design thesis. Semaglutide asks how far a single well-understood receptor can be pushed. Retatrutide asks whether adding a third, mechanistically distinct receptor changes the ceiling.

Chemical Structure diagram — Semaglutide: an acylated GLP-1 analogue built for a long half-life.

Evidence, framed honestly

·Semaglutide has the deepest evidence base in the class: completed phase 3 weight-management and diabetes programmes,[1] cardiovascular outcome trials in type 2 diabetes[2] and in obesity without diabetes,[5] and approvals in Canada and internationally for its pharmaceutical forms.
·Retatrutide has a phase 2 obesity trial reporting mean weight reductions larger than any single or dual agonist had reported at a comparable stage,[6] plus a phase 2 dataset in type 2 diabetes.[7] Phase 3 is the open question. No retatrutide product is approved anywhere in the world.
·Cross-phase comparisons are not head-to-head trials. A phase 2 mean is generated in a smaller, more selected population over a shorter horizon than a phase 3 programme. A larger phase 2 number is a reason to keep watching a mechanism, not a demonstration that it beats a completed programme.
·Neither research-grade compound has an established human safety record, and neither is authorised by Health Canada for human or veterinary use.

What the pairing is actually useful for

For a research panel the question is rarely which compound is better. It is which reference each one provides. Semaglutide is the well-characterised single-receptor comparator, the compound whose behaviour is documented well enough that a deviation in an assay is informative. Retatrutide is the multi-receptor frontier compound, where the interesting variable is what the glucagon arm contributes on top of the incretin pair.

Run together, they let a design separate incretin effects from the added glucagon mechanism, which is exactly the question the class is currently arguing about.

Verification, where this class is most exposed

GLP-1-class peptides are the most heavily counterfeited compounds in this market, and the problem is documented rather than anecdotal: a 2024 market-surveillance study of semaglutide products sold online without prescription found substantial quality and safety failures across sellers, including products that did not contain what the label claimed.[8]

Three figures settle it, and all three are needed. Mass-spectrometric identity establishes that the molecule is the one on the label, which matters most for expensive compounds where substituting a cheaper analogue is the profitable fraud. HPLC purity establishes what fraction of the content is that molecule. Measured mass establishes how much is in the vial, which purity is mathematically incapable of telling you. The reasoning is set out in purity vs fill accuracy and underfilled vials.

Both compounds here publish all three per lot before the lot goes on sale, and each certificate carries a key that resolves on the testing laboratory's own database.

Certificate of analysis for Buy Semaglutide Canada | GLP-1 10mg, batch SEMA-CA-26F-10, 99.504% purity, 11.27 mg measured content — Current published semaglutide certificate, by strength.

Certificate of analysis for Buy Retatrutide Canada | Triple Agonist 10mg, batch RETA-CA-26E-01, 99.637% purity, 11.76 mg measured content — Current published retatrutide certificate, by strength.

Selecting between them

If the research question needs a compound whose pharmacology is documented across completed trials, semaglutide is the one with that record. If the question is about multi-receptor agonism and specifically about what glucagon-receptor engagement adds, retatrutide is the compound that isolates it, with the standing caveat that its own record stops at phase 2.

Both are stocked, both publish a certificate per lot, and both are supplied strictly as research materials.

Available at Eppix Labs

Buy Semaglutide Canada | GLP-1

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $70.00 CADIn stock

Available at Eppix Labs

Buy Retatrutide Canada | Triple Agonist

10mg · 20mg · 40mg · 50mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $60.00 CADIn stock

Frequently Asked

Its phase 2 averages exceeded what semaglutide reported at a comparable stage, but a phase 2 result and a completed phase 3 programme are not directly comparable. Retatrutide remains investigational and is not approved anywhere.

In the published literature glucagon-receptor agonism is associated with increased energy expenditure. That is a different mechanism from the appetite and gastric-emptying effects the GLP-1 class works through, and it is the structural bet behind triple agonists.

Research-grade material of both may be supplied for laboratory research. Neither research product is authorised for human or veterinary use. Semaglutide also exists as approved pharmaceutical products, which are separate regulated medicines and are not what is sold here. This is general information, not legal advice.

A lot-linked certificate carrying mass-spectrometric identity, HPLC purity and measured content, with a verification key that resolves on the testing laboratory's own database. This class is the most counterfeited in the market, so all three figures matter.

It shares the GIP and GLP-1 arms with tirzepatide and adds glucagon-receptor agonism, so it is a different mechanism rather than a scaled version of the same one. The dedicated comparison is at retatrutide vs tirzepatide.

References

Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989-1002. PMID 33567185
Marso, S.P. et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834-1844. PMID 27633186
Coskun, T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 34(9):1234-1247. PMID 35985340
Lau, J. et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58(18):7370-7380. PMID 26308095
Lincoff, A.M. et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221-2232. PMID 37952131
Jastreboff, A.M. et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 389(6):514-526. PMID 37366315
Rosenstock, J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet 402(10401):529-544. PMID 37385280
Ashraf, A.R., Mackey, T.K., Vida, R.G. et al. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res 26:e65440. PMID 39509151

Buy Retatrutide Canada | Triple Agonist

From $60.00 CAD · Janoshik-verified COA

Buy Semaglutide Canada | GLP-1

From $70.00 CAD · Janoshik-verified COA

Research Use Only

This article summarizes published preclinical research literature. Compounds referenced are supplied by Eppix Labs strictly as research materials for laboratory investigation within Canada. They are not approved by Health Canada for human or veterinary use, and nothing on this page should be interpreted as medical advice or guidance on human or animal administration.